Skip to content
Screener

Veracyte VCYT Total Cost of Revenue

Total Cost of Revenue at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$62.8M+1.8%
Castle Biosciences logo
Castle BiosciencesCSTL
$20.53M+25.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
$15.19M+13.4%
Guardant Health logo
Guardant HealthGH
$104.92M+40.4%
Natera, Inc. logo
Natera, Inc.NTRA
$42.73M+3.3%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$282.7M+1.2%

Segments

By product

See full
Testing revenue$33.31M+17.9%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: Veracyte’s 10-K, filed February 25, 2020. Open the filing →

Filed
Feb 25, 2020, 4:29 PM EST
Fiscal year
FY2019
Accession
0001384101-20-000015

FAQ

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.